Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study To develop and validate nomograms for OS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback